Boston Scientific's ACURATE Neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024
Boston Scientific's ACURATE Neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024
波士頓科學的ACURATE Neo2主動脈瓣系統在關鍵試驗中未達到非劣效性標準，顯示一年內死亡率、中風率或再入院率的綜合率爲16.16％，而對照組閥門爲9.53％；數據在TCt 2024上呈現。
Boston Scientific's ACURATE Neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024
波士頓科學的ACURATE Neo2主動脈瓣系統在關鍵試驗中未達到非劣效性標準，顯示一年內死亡率、中風率或再入院率的綜合率爲16.16％，而對照組閥門爲9.53％；數據在TCt 2024上呈現。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間